cas 19748-66-4|| where to buy 1-(3-HYDROXYPROPYL)-PYRROLIDINE

Nombre del producto:1-(3-HYDROXYPROPYL)-PYRROLIDINE

IUPAC Name:3-(pyrrolidin-1-yl)propan-1-ol

Unidad de embalaje	Stock disponible	Precio($)
CM101545-10g	in stock	ǲǲ
CM101545-25g	in stock	ȦɐƤ
CM101545-100g	in stock	ȌǲȌ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 19748-66-4 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :19748-66-4; Fórmula molecular:C7H15NO; Punto de fusión:-; Código de sonrisas:OCCCN1CCCC1; Densidad:

: Número de catálogo:CM101545; Peso molecular:129.2; Punto de ebullición:216.9°C at 760 mmHg; Nº Mdl:MFCD01687769; Almacenamiento:Store at 2-8°C.

: Pyrrolidines; Pyrrolidine, also known as tetrahydropyrrole, is a saturated five-membered heterocyclic ring, which is miscible with water. Pyrrolidine exists in many alkaloids and drug molecules, such as kappa opioids, antagonists of dopamine D4 receptors, and HIV reverse transcriptase inhibitors.

: Pyrroles; Pyrrole is a five membered heterocyclic compound with the molecular formula of C4H5N. Pyrrole has a ring composed of four carbon atoms and one nitrogen atom. Pyrrole is easy to polymerize in the air. Pyrrole is the parent compound of many important biological substances (such as bile pigment, porphyrin and chlorophyll). Pyrrole scaffolds are widely used in biological and pharmaceutical fields. Pyrrole is a special heterocyclic scaffold, which exists in many natural products, drug molecules and pesticides, and has shown its application in materials science.

: IDRX-42; IDRx announces $120 million series B financing to advance potential best-in-class new treatment for gastrointestinal stromal tumor (GIST). IDRX-42 is a potent, oral, highly selective KIT inhibitor targeting all major categories of activating and resistance mutations in patients with KIT-mutant GIST (including variants in exons 9, 11, 13 and 17). IDRX-42 was granted Orphan Drug designation by the FDA for the treatment of GIST. IDRX-42 is currently being evaluated in StrateGIST 1, a first-in-human Phase 1/1b study.
In preclinical studies, IDRX-42 demonstrated superior antitumor activity compared to imatinib, the current first-line of therapy, in GIST human xenograft models expressing mutations in KIT exons 9 and 11. In xenograft models expressing secondary resistance mutations in KIT exon 13 or 17, IDRX-42 treatment resulted in potent and dose-dependent antitumor activity superior to the second-line standard of care agent, sunitinib.